Product Information
Registration Status: ActiveSIN11820P
MYOVIEW FOR INJECTION 0.23mg/VIAL is approved to be sold in Singapore with effective from 2002-02-25. It is marketed by GE HEALTHCARE PTE LTD, with the registration number of SIN11820P.
This product contains Tetrofosmin 0.23mg/vial in the form of INJECTION, POWDER, FOR SOLUTION. It is approved for INTRAVENOUS use.
This product is manufactured by GE HEALTHCARE AS (OSLO SITE) in NORWAY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Tetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds. It presents a molecular formula of 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane. Tetrofosmin is part of the group of diphosphines. The sell of tetrofosmin in a freeze-dried kit is FDA approved and it is always accompanied by technetium Tc-99m as a radiopharmaceutical.[A7788]
Indication
Tetrofosmin is indicated to be used as a complex with technetium Tc-99m for scintigraphic imaging of the myocardium following separate administrations under exercise and/or resting conditions. It helps in the delineation of regions of reversible myocardial ischemia in absence of infarcted myocardium.[L2001] This complex is also used for scintigraphic imaging of the myocardium to identify changes in perfusion induced by pharmacologic stress in patients with known or suspected coronary artery disease.[L2001] This complex is indicated for the assessment of left ventricular function in patients evaluated for heart disease.[L2001]
Mechanism of Action
Tetrofosmin normal biodistribution makes it suitable to be used as a myocardial agent as it is uptaken by the myocardial tissue and it presents a very low redistribution after 3-4 hours of administration.[A32342] After distribution, tetrofosmin is a lipophilic cationic agent which is passively diffused and accumulated in viable myocardial tissue.[T82]
Pharmacokinetics
- Absorption
- After intravenous administration, tetrofosmin is rapidly cleared from the blood and taken up by the heart, skeletal muscle, liver, spleen and kidneys.[A32342]
- Distribution
- This pharmacokinetic property has not been fully studied.
- Metabolism
- This pharmacokinetic property has not been fully studied.
- Elimination
Clearance
Refer to [DB09160]
Toxicity
The toxicity of tetrofosmin as an individual agent has not been studied.
Active Ingredient/Synonyms
Tetrofosmin | Tetrofosmin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.